Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.140
-0.030 (-1.38%)
At close: Aug 26, 2026, 4:00 PM EDT
2.135
-0.005 (-0.23%)
After-hours: Aug 26, 2026, 7:30 PM EDT
Century Therapeutics Revenue
In the year 2025, Century Therapeutics had annual revenue of $109.16M with 1,556.76% growth.
Revenue (ttm)
$109.16M
Revenue Growth
+1,556.76%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
78
Market Cap
387.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.16M | 102.58M | 1,556.76% |
| Dec 31, 2024 | 6.59M | 4.35M | 194.81% |
| Dec 31, 2023 | 2.24M | -2.96M | -57.01% |
| Dec 31, 2022 | 5.20M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 59.22M |
| Foghorn Therapeutics | 36.74M |
| Arcturus Therapeutics Holdings | 29.37M |
| X4 Pharmaceuticals | 15.85M |
| Capricor Therapeutics | 11.13M |
| Upstream Bio | 3.16M |
| Lyell Immunopharma | 27.00K |
IPSC News
- 9 days ago - Century Therapeutics reports Q2 EPS (17c), consensus (12c) - TheFly
- 14 days ago - Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 14 days ago - Century Therapeutics Quarterly report: Q2 2026 - Filings
- 14 days ago - Century Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group - Business Wire
- 6 weeks ago - Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - GlobeNewsWire
- 2 months ago - Century Therapeutics presents new preclinical data for CNTY-813 - TheFly
- 2 months ago - New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 - GlobeNewsWire